Terms: = Prostate cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4 AND Treatment
30 results:
1. Dibutylstannanediyl (2Z,2'Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK/PPARα/smad4 signaling.
Waseem D; Khan GM; Haq IU; Syed DN
Toxicol Appl Pharmacol; 2022 Aug; 449():116127. PubMed ID: 35705140
[TBL] [Abstract] [Full Text] [Related]
2. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract] [Full Text] [Related]
3. Synthesis of Silica Based Nanoparticles Against the Proliferation of Human prostate cancer.
Durmus IM; Deveci I; Karakurt S
Anticancer Agents Med Chem; 2021; 21(18):2553-2562. PubMed ID: 33557739
[TBL] [Abstract] [Full Text] [Related]
4. Up-regulation of TIF1γ by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-β/Smad signaling pathway.
Qi G; Lu G; Yu J; Zhao Y; Wang C; Zhang H; Xia Q
Eur J Pharmacol; 2019 Oct; 860():172551. PubMed ID: 31323225
[TBL] [Abstract] [Full Text] [Related]
5. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract] [Full Text] [Related]
6. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant prostate cancers.
Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
[TBL] [Abstract] [Full Text] [Related]
7. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Feng S; Cheng X; Zhang L; Lu X; Chaudhary S; Teng R; Frederickson C; Champion MM; Zhao R; Cheng L; Gong Y; Deng H; Lu X
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10094-10099. PubMed ID: 30232256
[TBL] [Abstract] [Full Text] [Related]
8. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and smad4 in prostate cancer.
Li X; Li J; Cai Y; Peng S; Wang J; Xiao Z; Wang Y; Tao Y; Li J; Leng Q; Wu D; Yang S; Ji Z; Han Y; Li L; Gao X; Zeng C; Wen X
Cancer Lett; 2018 Apr; 418():211-220. PubMed ID: 29331421
[TBL] [Abstract] [Full Text] [Related]
9. SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of prostate cancer Cells via Regulating smad4 deSUMOylation.
Zhang X; Wang H; Wang H; Xiao F; Seth P; Xu W; Jia Q; Wu C; Yang Y; Wang L
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417919
[TBL] [Abstract] [Full Text] [Related]
10. CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling.
Tseng JC; Lin CY; Su LC; Fu HH; Yang SD; Chuu CP
Oncotarget; 2016 Jun; 7(25):38010-38024. PubMed ID: 27191743
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract] [Full Text] [Related]
12. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of smad4.
Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
[TBL] [Abstract] [Full Text] [Related]
13. Cryoablation induced the change of TGF-β pathway in CWR-22RV prostate cancer cell line.
Nailing T; Zhi G; Xueling Y
Cryobiology; 2015 Aug; 71(1):130-4. PubMed ID: 25952505
[TBL] [Abstract] [Full Text] [Related]
14. Recent trends in testosterone testing, low testosterone levels, and testosterone treatment among Veterans.
Walsh TJ; Shores MM; Fox AE; Moore KP; Forsberg CW; Kinsey CE; Heckbert SR; Zeliadt S; Thompson ML; Smith NL; Matsumoto AM
Andrology; 2015 Mar; 3(2):287-92. PubMed ID: 25684636
[TBL] [Abstract] [Full Text] [Related]
15. prostate apoptosis response-4 mediates TGF-β-induced epithelial-to-mesenchymal transition.
Chaudhry P; Fabi F; Singh M; Parent S; Leblanc V; Asselin E
Cell Death Dis; 2014 Feb; 5(2):e1044. PubMed ID: 24503536
[TBL] [Abstract] [Full Text] [Related]
16. Role of smad4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.
Jiang W; Zheng Y; Huang Z; Wang M; Zhang Y; Wang Z; Jin X; Xia Q
Int Urol Nephrol; 2014 May; 46(5):941-6. PubMed ID: 24265041
[TBL] [Abstract] [Full Text] [Related]
17. Current mouse and cell models in prostate cancer research.
Wu X; Gong S; Roy-Burman P; Lee P; Culig Z
Endocr Relat Cancer; 2013 Aug; 20(4):R155-70. PubMed ID: 23580590
[TBL] [Abstract] [Full Text] [Related]
18. microRNA-183 is an oncogene targeting Dkk-3 and smad4 in prostate cancer.
Ueno K; Hirata H; Shahryari V; Deng G; Tanaka Y; Tabatabai ZL; Hinoda Y; Dahiya R
Br J Cancer; 2013 Apr; 108(8):1659-67. PubMed ID: 23538390
[TBL] [Abstract] [Full Text] [Related]
19. [Radical transurethral resection of the prostate. An alternative therapy for the treatment of prostate cancer].
Reuter MA; Dietz K
Urologe A; 2009 Jul; 48(7):740-7. PubMed ID: 19484215
[TBL] [Abstract] [Full Text] [Related]
20. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers.
Hird A; Chow E; Zhang L; Wong R; Wu J; Sinclair E; Danjoux C; Tsao M; Barnes E; Loblaw A
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):193-7. PubMed ID: 19167840
[TBL] [Abstract] [Full Text] [Related]
[Next]
